NASDAQ:OPGN - OpGen Stock Price, Price Target & More

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

OpGen's stock reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

OpGen (NASDAQ:OPGN) issued its quarterly earnings results on Thursday, March, 15th. The medical research company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.05. The medical research company earned $0.99 million during the quarter, compared to analysts' expectations of $0.81 million. OpGen had a negative return on equity of 1,719.89% and a negative net margin of 479.38%. View OpGen's Earnings History.

OpGen is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for OpGen.

2 Wall Street analysts have issued 12 month price objectives for OpGen's stock. Their predictions range from $9.00 to $9.00. On average, they expect OpGen's share price to reach $9.00 in the next year. View Analyst Ratings for OpGen.

Some companies that are related to OpGen include Oncobiologics (ONS), IntelliPharmaCeutics Intl (IPCI), ContraVir Pharmaceuticals (CTRV), Dynatronics (DYNT), DelMar Pharmaceuticals (DMPI), AmpliPhi Biosciences (APHB), Bio-Path (BPTH), EnteroMedics (RSLS), Cellectar Biosciences (CLRB), ESSA Pharma (EPIX), Cesca Therapeutics (KOOL), Cormedix (CRMD), Prana Biotechnology (PRAN), Sonoma Pharmaceuticals (SNOA), Fibrocell (FCSC), TrovaGene (TROV), ValiRx (VAL) and Cyclacel (CYCC).

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

Headlines about OPGN stock have trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OpGen earned a daily sentiment score of 0.17 on Accern's scale. They also gave media headlines about the medical research company an impact score of 46.23 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

OpGen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (5.17%) and SABBY MANAGEMENT, LLC (5.17%). Company insiders that own OpGen stock include Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen.

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OPGN stock can currently be purchased for approximately $2.05.

OpGen has a market capitalization of $11.53 million and generates $3.21 million in revenue each year. The medical research company earns $-15,410,000.00 in net income (profit) each year or ($9.78) on an earnings per share basis. OpGen employs 43 workers across the globe.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]